Korea Investment CORP Sells 72,153 Shares of Zoetis Inc. $ZTS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Korea Investment CORP cut its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 22.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 256,003 shares of the company's stock after selling 72,153 shares during the period. Korea Investment CORP owned about 0.06% of Zoetis worth $42,151,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter worth about $30,000. Cornerstone Planning Group LLC increased its holdings in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after buying an additional 120 shares during the last quarter. Sound Income Strategies LLC increased its holdings in shares of Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares during the last quarter. Finally, Bfsg LLC increased its holdings in shares of Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after buying an additional 252 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.18% of the company's stock.

Zoetis Trading Down 0.8%

Zoetis stock traded down $1.2650 during trading hours on Thursday, hitting $155.4950. The company had a trading volume of 2,411,616 shares, compared to its average volume of 3,540,633. The firm has a market cap of $68.91 billion, a P/E ratio of 26.76, a P/E/G ratio of 2.52 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a 50-day moving average price of $154.00 and a two-hundred day moving average price of $158.75.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ZTS shares. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.